Altshuler Shaham’s Travere Therapeutics TVTX Stock Holding History

Altshuler Shaham’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,435	Closed	-$37K	–	561
2022 Q1	$37K	Sell	1,435 -228	-14%	-$6.05K	﹤0.01%	451
2021 Q4	$52K	Buy	+1,663	New	+$46.8K	﹤0.01%	407
2021 Q2	–	Sell	-1,447	Closed	-$36K	–	743
2021 Q1	$36K	Buy	+1,447	New	+$40K	﹤0.01%	344
2020 Q2	–	Sell	-5,329	Closed	-$78K	–	566
2020 Q1	$78K	Sell	5,329 -716	-12%	-$10.8K	﹤0.01%	176
2019 Q4	$86K	Sell	6,045 -28,800	-83%	-$368K	﹤0.01%	181
2019 Q3	$396K	Buy	34,845 +262	+0.8%	+$4.33K	0.02%	96
2019 Q2	$695K	Buy	34,583 +1,116	+3%	+$22K	0.03%	92
2019 Q1	$757K	Hold	33,467	–	–	0.03%	94
2018 Q4	$757K	Sell	33,467 -95	-0.3%	-$2.36K	0.03%	90
2018 Q3	$964K	Hold	33,562	–	–	0.05%	89
2018 Q2	$915K	Buy	33,562 +8,100	+32%	+$216K	0.08%	86
2018 Q1	$569K	Buy	25,462 +762	+3%	+$18.1K	0.08%	92
2017 Q4	$520K	Buy	+24,700	New	+$565K	0.07%	83

Other funds holding TVTX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Altshuler Shaham's TVTX Position: Q2 2022 in Review

Altshuler Shaham sold out of Travere Therapeutics (TVTX) in Q2 2022, closing a stake of 1,435 shares — an estimated $37K sold.

Altshuler Shaham first reported a position in TVTX in Q4 2017 and held it in 13 quarters. The position peaked at $964K in Q3 2018. 171 funds tracked by Wall St. Rank hold TVTX as of Q2 2022.

Altshuler Shaham reported no remaining Travere Therapeutics position as of Q2 2022 after selling out during the quarter.
Altshuler Shaham sold 1,435 Travere Therapeutics shares in Q2 2022, an estimated $37K.
Altshuler Shaham first reported a position in Travere Therapeutics in Q4 2017 and held it in 13 quarters.
Altshuler Shaham's Travere Therapeutics position peaked at $964K in Q3 2018.
171 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2022.

Based on Altshuler Shaham's 13F filing for Q2 2022, filed 10 Aug 2022.